Minnesota’s bioscience industry is an innovative and growing component of the overall U.S. economy. With a track record of generating high-quality jobs and steady growth, the bioscience industry has been a consistent engine for our economy and a key strength during past economic recessions. American innovation in bioscience helps support state and local communities in a variety of ways ranging from job creation, construction, tax revenues, and other economic impact values.

Driven by small-company innovators, the bioscience industry has also mobilized in an unprecedented manner to address the global COVID-19 pandemic, while continuing to develop other life-saving and life-enhancing products and services for the U.S. and the world. America’s bioscience industry as an innovator and economic driver has never been more important, both for our health and our economic stability.

Total Number of Facilities in Minnesota 35
Jobs Directly Supported by the Industry in Minnesota 63338
Annual Average Wage
Total Clinical Trials
Dollar Amount Invested in Clinical Trials
$218 Million
Clinical Trial Participants
Total Clinical Trial Economic Impact
$629.8 Million

View Facilities By District

District Total Facilities in District View Facilities in District
MN01 11 Agri-Energy (A)

Bayer (H)

Cargill, Incorporated (A)

Gevo Inc. (A)

Mayo Clinic (O)

Mayo Clinic Ventures (O)

Mayo Clinical Trial Services (O)

Mayo Foundation For Medical Education & Research (O)

Poet (A) (3)

MN02 2 BASF Corp (A)

Recombinetics, Inc (A)

MN03 4 Cargill Ventures (A)

Cargill, Inc. (A)

Genmab MN, Inc (H)

MGI Pharma, Inc (H)

MN04 3 Acceligen – A Recombinetics Company (A)

Calyxt, Inc. (A)

Rebiotix Inc. (H)

MN05 5 BioBusiness Alliance of Minnesota (O)

Cargill (A)

Medical Alley Association (O)

TH!NK DIFFERENT Foundation (O)

TTC Oncology LLC (H)

MN06 1 Cargill, Incorporated (A) (2)
MN07 4 BASF Corp (A)

Bayer (H)

Green Biologics (A)

Poet (A)